Logo do repositório
 
Publicação

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease

2018-02-18Recensão Acesso aberto
Ver registo simples
dc.contributor.authorKönig, Annekatrin
dc.contributor.authorVicente Miranda, Hugo
dc.contributor.authorOuteiro, Tiago Fleming
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblIOS Press
dc.date.accessioned2022-12-28T22:09:34Z
dc.date.available2022-12-28T22:09:34Z
dc.date.issued2018-02-18
dc.descriptionFunding: Tecnologia (FCT), Portugal (SFRH/BPD/109347/ 2015; PTDC/NEU-OSD/5644/2014). TFO is supported by the DFG Center for Nanoscale Microscopy of the Brain (CNMPB) and by an EU Joint Programme – Neurodegenerative Disease Research (JPND) project (aSynProtec). The project is supported through the following funding organisations under the aegis of JPND – www.jpnd.edu (BMBF).
dc.description.abstractParkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent11
dc.format.extent266099
dc.identifier.doi10.3233/JPD-171285
dc.identifier.issn1877-7171
dc.identifier.otherPURE: 3657807
dc.identifier.otherPURE UUID: 7138ee80-d65f-49d7-8e33-9ba0faa071b3
dc.identifier.otherPubMed: 29480231
dc.identifier.otherWOS: 000425657100004
dc.identifier.otherScopus: 85043588925
dc.identifier.urihttp://hdl.handle.net/10362/146708
dc.language.isoeng
dc.peerreviewedyes
dc.subjectGlycation
dc.subjectMaillard-reaction
dc.subjectParkinson’s disease
dc.subjectalpha-synuclein
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAlpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Diseaseen
dc.typereview
degois.publication.firstPage33
degois.publication.issue1
degois.publication.lastPage43
degois.publication.titleJournal of Parkinson's Disease
degois.publication.volume8
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
jpd_2018_8_1_jpd_8_1_jpd171285_jpd_8_jpd171285.pdf
Tamanho:
259.86 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica